48,466
edits
Difference between revisions of "Malignant mesothelioma"
Jump to navigation
Jump to search
Malignant mesothelioma (view source)
Revision as of 18:43, 10 February 2022
, 18:43, 10 February 2022→Mesothelioma versus mesothelial hyperplasia
| (11 intermediate revisions by 2 users not shown) | |||
| Line 33: | Line 33: | ||
==General== | ==General== | ||
*Incidence | |||
**Rare tumor accounting for 4-7 cases per million individuals. | |||
**More common in men in 5th and 6th decades of life. | |||
*Poor prognosis<ref>{{Cite journal | last1 = Haber | first1 = SE. | last2 = Haber | first2 = JM. | title = Malignant mesothelioma: a clinical study of 238 cases. | journal = Ind Health | volume = 49 | issue = 2 | pages = 166-72 | month = | year = 2011 | doi = | PMID = 21173534 }}</ref> - median survival <12 months.<ref name=pmid23413596>{{Cite journal | last1 = Mineo | first1 = TC. | last2 = Ambrogi | first2 = V. | title = Malignant pleural mesothelioma: factors influencing the prognosis. | journal = Oncology (Williston Park) | volume = 26 | issue = 12 | pages = 1164-75 | month = Dec | year = 2012 | doi = | PMID = 23413596 }}</ref> | *Poor prognosis<ref>{{Cite journal | last1 = Haber | first1 = SE. | last2 = Haber | first2 = JM. | title = Malignant mesothelioma: a clinical study of 238 cases. | journal = Ind Health | volume = 49 | issue = 2 | pages = 166-72 | month = | year = 2011 | doi = | PMID = 21173534 }}</ref> - median survival <12 months.<ref name=pmid23413596>{{Cite journal | last1 = Mineo | first1 = TC. | last2 = Ambrogi | first2 = V. | title = Malignant pleural mesothelioma: factors influencing the prognosis. | journal = Oncology (Williston Park) | volume = 26 | issue = 12 | pages = 1164-75 | month = Dec | year = 2012 | doi = | PMID = 23413596 }}</ref> | ||
| Line 77: | Line 80: | ||
DDx:<ref name=pmid15559051>{{Cite journal | last1 = Corson | first1 = JM. | title = Pathology of mesothelioma. | journal = Thorac Surg Clin | volume = 14 | issue = 4 | pages = 447-60 | month = Nov | year = 2004 | doi = 10.1016/j.thorsurg.2004.06.007 | PMID = 15559051 }} | DDx:<ref name=pmid15559051>{{Cite journal | last1 = Corson | first1 = JM. | title = Pathology of mesothelioma. | journal = Thorac Surg Clin | volume = 14 | issue = 4 | pages = 447-60 | month = Nov | year = 2004 | doi = 10.1016/j.thorsurg.2004.06.007 | PMID = 15559051 }} | ||
</ref> | </ref> | ||
<ref name="pmid15725802">{{Cite journal | last1 = Bégueret | first1 = H. | last2 = Galateau-Salle | first2 = F. | last3 = Guillou | first3 = L. | last4 = Chetaille | first4 = B. | last5 = Brambilla | first5 = E. | last6 = Vignaud | first6 = JM. | last7 = Terrier | first7 = P. | last8 = Groussard | first8 = O. | last9 = Coindre | first9 = JM. | title = Primary intrathoracic synovial sarcoma: a clinicopathologic study of 40 t(X;18)-positive cases from the French Sarcoma Group and the Mesopath Group. | journal = Am J Surg Pathol | volume = 29 | issue = 3 | pages = 339-46 | month = Mar | year = 2005 | doi = | PMID = 15725802 }}</ref> | |||
*[[Fibrosing pleuritis]] - should ''not'' have nodules, more cellular on the aspect adjacent to the effusion. | *[[Fibrosing pleuritis]] - should ''not'' have nodules, more cellular on the aspect adjacent to the effusion. | ||
*Reactive mesothelial cells - may be atypical. | *Reactive mesothelial cells - may be atypical. | ||
| Line 82: | Line 86: | ||
*[[Adenocarcinoma]] - esp. [[lung adenocarcinoma]]. | *[[Adenocarcinoma]] - esp. [[lung adenocarcinoma]]. | ||
*[[Serous carcinoma]]. | *[[Serous carcinoma]]. | ||
*[[Synovial sarcoma]]. | |||
===Images=== | ===Images=== | ||
| Line 93: | Line 98: | ||
Image: Malignant epithelioid mesothelioma - calretinin - high mag.jpg | MM - calretinin - high mag. | Image: Malignant epithelioid mesothelioma - calretinin - high mag.jpg | MM - calretinin - high mag. | ||
</gallery> | </gallery> | ||
====www==== | |||
*[http://www.rosaicollection.org/searchresults.cfm/ Mesothelioma (rosaicollection.org/index.cfm)]. | |||
===Subtypes=== | ===Subtypes=== | ||
| Line 115: | Line 123: | ||
*EMA +ve ~100% (vs. ~10%). | *EMA +ve ~100% (vs. ~10%). | ||
*Desmin -ve ~5% (vs. ~85%). | *Desmin -ve ~5% (vs. ~85%). | ||
*GLUT1 +ve ~50% (vs. ~10%) | *GLUT1 +ve ~50% (vs. ~10%). | ||
*p53 +ve ~50% (vs. ~2%). | *p53 +ve ~50% (vs. ~2%). | ||
*BAP1 -ve<ref name=pmid29085180>{{cite journal |authors=Pulford E, Huilgol K, Moffat D, Henderson DW, Klebe S |title=Malignant Mesothelioma, BAP1 Immunohistochemistry, and VEGFA: Does BAP1 Have Potential for Early Diagnosis and Assessment of Prognosis? |journal=Dis Markers |volume=2017 |issue= |pages=1310478 |date=2017 |pmid=29085180 |pmc=5612603 |doi=10.1155/2017/1310478 |url=}}</ref> ~57%.<ref name=pmid26226841>{{cite journal |authors=Andrici J, Sheen A, Sioson L, Wardell K, Clarkson A, Watson N, Ahadi MS, Farzin M, Toon CW, Gill AJ |title=Loss of expression of BAP1 is a useful adjunct, which strongly supports the diagnosis of mesothelioma in effusion cytology |journal=Mod Pathol |volume=28 |issue=10 |pages=1360–8 |date=October 2015 |pmid=26226841 |pmc=4761613 |doi=10.1038/modpathol.2015.87 |url=}}</ref> | |||
Note: | Note: | ||
| Line 138: | Line 147: | ||
**MOC-31. | **MOC-31. | ||
**CD15. | **CD15. | ||
**[[B72.3]]. | |||
===Other carcinoma markers=== | ===Other carcinoma markers=== | ||